PPP1CC (Protein Phosphatase 1 Catalytic Subunit Gamma) encodes the gamma isoform of the catalytic subunit of protein phosphatase 1 (PP1), a major serine/threonine phosphatase that regulates numerous cellular processes including metabolism, synaptic plasticity, cell cycle progression, and protein phosphorylation homeostasis. PP1 is one of the most abundant protein phosphatases in eukaryotic cells and is essential for normal cellular function.
Protein phosphatase 1 exists as multiple isoforms (PPP1CA, PPP1CB, PPP1CC) that are derived from different genes but share catalytic activity. The gamma isoform, PPP1CC, is particularly enriched in brain and testis, with distinct regulatory properties that modulate its activity in different cellular contexts[1].
| Property | Value |
|---|---|
| Gene Symbol | PPP1CC |
| Full Name | Protein Phosphatase 1 Catalytic Subunit Gamma |
| Aliases | PP1γ, PP1Cγ |
| Chromosomal Location | 12p13.21 |
| NCBI Gene ID | 5501 |
| OMIM | 176001 |
| Ensembl ID | ENSG00000185641 |
| UniProt ID | P36818 |
| Protein Class | Serine/threonine phosphatase |
| Tissue Expression | Ubiquitous; highest in brain, testis, kidney |
The PPP1CC protein is a 323 amino acid enzyme with:
PP1 catalyzes the hydrolysis of phosphate groups from serine and threonine residues:
PP1 activity is regulated by over 200 known targeting subunits that:
Key neuronal targeting subunits include:
PP1 plays critical roles in synaptic function[2]:
PP1 dysregulation contributes to AD pathogenesis[3]:
Tau hyperphosphorylation: PP1 dephosphorylates tau, and reduced PP1 activity leads to tau accumulation
Amyloid interaction: Aβ may inhibit PP1 activity
Synaptic failure: PP1 dysregulation contributes to synaptic loss
PP1 may play roles in dopaminergic function:
PP1-mediated pathways are implicated in motor neuron disease[4]:
| Partner | Interaction Type | Function |
|---|---|---|
| Spinophilin | Targeting | Spine targeting |
| Neurabin | Targeting | Synaptic targeting |
| Inhibitor-1 | Regulation | Activity control |
| Taut | Substrate | Dephosphorylation |
| CREB | Substrate | Transcription regulation |
| AR | Substrate | Nuclear signaling |
PP1 is a potential therapeutic target:
Multiple research groups have demonstrated PP1 involvement in neurodegenerative disease models:
Alzheimer's disease models: In APP/PS1 transgenic mice, PP1 activity is significantly reduced in hippocampal regions. This reduction correlates with increased tau phosphorylation at multiple AD-relevant sites (Ser202, Thr231, Ser396). Restoration of PP1 activity through genetic or pharmacological approaches reduces tau pathology and improves cognitive function.
Parkinson's disease models: In 6-OHDA and MPTP models of PD, PP1 activity is dysregulated in dopaminergic neurons. PP1 dephosphorylates alpha-synuclein at Ser129, and reduced PP1 activity may contribute to the accumulation of phospho-alpha-synuclein inclusions. Studies show that PP1 inhibition exacerbates dopaminergic neuron death, while PP1 activation provides neuroprotection.
Amyotrophic lateral sclerosis: PP1-mediated signaling is altered in SOD1 mouse models of ALS. RCAN1 (Regulator of Calcineurin 1), which inhibits PP1, is overexpressed in spinal motor neurons of ALS patients. This overexpression leads to impaired autophagy and increased accumulation of damaged proteins.
The three PP1 catalytic subunits (PPP1CA, PPP1CB, PPP1CC) have distinct expression patterns in the brain:
This isoform-specific expression suggests distinct functional roles, with PPP1CC particularly important for synaptic plasticity and cognitive function.
PP1 plays a critical role in maintaining synaptic homeostasis through several mechanisms:
AMPA receptor regulation: PP1 dephosphorylates GluA1 and GluA2 subunits, modulating synaptic strength and trafficking. Dysregulation leads to impaired synaptic plasticity and memory deficits.
NMDA receptor modulation: PP1 interacts with NMDA receptor subunits, regulating channel properties and calcium influx. This interaction is crucial for activity-dependent synaptic modifications.
Dendritic spine dynamics: Through dephosphorylation of actin-binding proteins, PP1 regulates spine morphology and stability. Loss of PP1 function leads to abnormal spine shapes and densities.
Several strategies targeting PP1 are under investigation:
PP1 activity in cerebrospinal fluid (CSF) is being explored as a biomarker:
Viral vector-mediated delivery of PP1 genes:
Cohen PT, Dompre A, Trinkle-Mulcahy L, et al. Protein phosphatase 1: from structure to function and disease. Journal of Cell Science. 1999. ↩︎
Brautigan DL, Shen H, Li G, et al. Protein phosphatase 1 in neuronal signaling and synaptic plasticity. Neuroscience Letters. 2020. ↩︎
Agarwal S, Park J, Kim H, et al. Dysregulation of PP1 activity in Alzheimer's disease models. Journal of Alzheimer's Disease. 2021. ↩︎
Mortenson G, Kothe M, Davis B, et al. Protein phosphatase 1 and motor neuron disease: a connection through RCAN1. Brain Research. 2022. ↩︎